Chronic phase
Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase
... Abstract: Imatinib mesylate (IM), an original Abl tyrosine kinase inhibitor, entered the clinics in 1998 for the treatment of patients with chronic myeloid leukemia (CML). The drug is universally considered the ...
9
Phase distribution of chronic myeloid leukemia in Bangladesh
... the phase distribution of chronic myeloid leukemia (CML), defined based on the World Health Organization criteria, among 63 patients in ...the chronic phase (CP), 7 (11%) in the accelerated ...
7
Benefits of global partnerships to facilitate access to medicines in developing countries: a multi-country analysis of patients and patient outcomes in GIPAP
... Current phase is ordered in a logical sequence, depending on the severity of the dis- ease, assigning different values to the different phases: 1 for blast crisis, 2 for accelerated phase, 3 for ...
13
Imatinib in the treatment of chronic myeloid leukemia: current perspectives on optimal dose
... 111 patients in newly diagnosed AP treated with imatinib at a dose of 600 mg daily. Imatinib was given in doses of 600 mg daily to all patients. Treatment was continued until disease progression, death, intolerance to ...
8
Deletion of Two Genes in Burkholderia pseudomallei MSHR668 That Target Essential Amino Acids Protect Acutely Infected BALB c Mice and Promote Long Term Survival
... acute phase of infection (21 and 25 days, respectively), and five mice from each group survived the challenge (MTD ...the chronic phase of ...acute phase of infection as well as the 668 ∆hisF ...
21
Case Report Severe peripheral arterial occlusive disease in chronic myeloid leukemia patient during nilotinib therapy: report of a case and review of literature
... PAOD is an increasingly emerging issue in patients with CML receiving nilotinib therapy. In recent years, several studies have been re- ported (Table 1) [7, 10, 12-15]. Eleven of 179 CML patients who received nilotinib ...
5
Bosutinib in the management of chronic myelogenous leukemia
... with chronic, accelerated, or blast-phase Philadelphia chromosome-positive chronic myelogenous leukemia who are intolerant of or resistant to first- or second-generation tyrosine kinase ...in ...
8
An Observational study of Non-adherence in Patients with Chronic Myeloid Leukemia on Treatment with Imatinib – Prevalence, Predictors and Outcomes.
... accelerated phase/blast crisis was 97% ...in chronic phase treated with imatinib have shown low rates of transformation to accelerated phase/blast crisis - 7% of patients progressed to ...
102
<p>Durable Molecular Remission in a Lymphoid BP-CML Patient Harboring T315I Mutation Treated with Anti-CD19 CAR-T Therapy</p>
... blast phase was unavoidable. Today, the occurrence of blast phase is about 1% annually, 37 for which the suggested treatment objective is to either push the disease progression back into the chronic ...
7
Activation of the hedgehog pathway in chronic myelogeneous leukemia patients
... The outcome for CML patients has been dramatically improved with the use of tyrosine kinase inhibitors (TKIs), leading to response rates of greater than 95% [16]. Although it is very effective in treating chronic ...
5
CD4+CD25+ regulatory cells contribute to the regulation of colonic Th2 granulomatous pathology caused by schistosome infection.
... It was not possible to obtain sufficient numbers of viable lymphocytes via enzymatic digestion of granulomatous colons due to the fibrotic nature of these intestinal granulomas but levels of IL-4 and IL-5 in whole ...
11
Bosutinib: a SRC–ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia
... of chronic myeloid ...in chronic myeloid leukemia, especially in the chronic phase, with resistance or intolerance to prior tyrosine kinase ...
6
Resistant mutations in CML and Ph<sup>+</sup>ALL – role of ponatinib
... with chronic phase (CP)-CML (Table 2) had a complete hema- tologic response (see Table 3 for clinical terms); 31/43 (72%) had a major cytogenetic response (MCyR), 27/43 (63%) had a complete cytogenetic ...
12
Effects of ghrelin supplementation on the acute phase of Chagas disease in rats
... Despite the efforts to develop new drugs and preven- tive approaches [3–6], there are only two available drugs (benznidazole and nifurtimox), which demonstrate side- effects and a limited anti-T. cruzi action [7]. Thus, ...
14
Targeted treatment of chronic myeloid leukemia: role of imatinib
... the chronic phase, the progenitor cells retain their ability to differentiate to myeloid lineage cells, but as the disease progresses to accelerated phase and blast crisis (AP and BC) differentiation ...
10
Clinical and Biological Features at Diagnosis in 40 Children With Chronic Myeloid Leukemia
... We reviewed the records of 40 children and adolescents who were treated for CML in 16 French centers. Among them, 12 consecutive children were included in the randomized trial LMC 91 protocol between January 1991 and May ...
6
Vol 32, No 7-8 (2019)
... of chronic myeloid leukemia therapy was disease control with the best overall survival, which required life- long ...concerning chronic phase-chronic myeloid leukemia patients who wish to ...
8
Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia
... CML chronic phase or accelerated phase with resistance and/or intolerance to two or more TKIs, its effectiveness in treating these patients has been ...
10
Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec<sup>®</sup>, Gleevec™)
... in chronic phase CML patients resistant or intolerant to interferon- α further emphasized its exceptional potency (Kantarjian et al 2002a, b; Cervantes et al 2003; Kantarjian et al 2004a; Rosti et al 2004; ...
26
Spotlight on nilotinib in the treatment of chronic myelogenous leukemia
... than chronic myelogenous leukemia ...with chronic or accelerated-phase ...treatment-naïve chronic-phase CML. Data also exist for blast-phase disease, which allows nilotinib to be ...
7